Forward P/S Multiple: Sight Sciences (SGHT)
Sight Sciences, Inc. (SGHT) develops OMNI ophthalmological systems for the implant-free treatment of glaucoma. While electronics supply chain risks constrain expansion, the humanitarian status of the equipment ensures stable global sales. The expected price-to-sales ratio demonstrates asset valuation dynamics, where the value of 6.70 reflects this status, signaling the current momentum of capital inflow into the company.
Summary analytical data breakdowns for Sight Sciences, Inc. (SGHT)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Sight Sciences, Inc.|SGHT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital sightsciences.com|SGHT - Company Aggregate Debts|Debt to Book Capitalization Ratio Sight Sciences|SGHT - Company Long-Term Debt|Company Current Liabilities Sight Sciences, Inc.|Quick Ratio sightsciences.com
- financial results and valuation multiples details:
SGHT - Company Net Income|Expected Profit Sight Sciences, Inc.|SGHT - Market Cap to Net Income Ratio|Projected Price to Earnings Sight Sciences Inc|SGHT - PEG Multiple|EV/EBITDA Multiple Sight Sciences, Inc|SGHT - Operating income before deduction of amortization|Earnings per share for the last twelve months Sight Sciences, Inc.|SGHT - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months sightsciences.com|SGHT - Net earnings per share growth this year|Earnings growth forecast for next year Sight Sciences, Inc.
- sales and revenue indicators:
Fundamental company analysis:SGHT (Sight Sciences, Inc)
Steady demand for Sight Sciences (SGHT) ocular microsurgery consumables drives the forward P/S dynamics, reflecting market expectations for revenue scaling. This multiple compares current market capitalization to expected revenue, where elevated values signal an overbought asset, while low values indicate an undervaluation of the innovative tools' potential within future cash flow structures.
Who Sight Sciences, Inc. competes with
Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple AORT (artivion.com)|Forward P/S Multiple Enovis Corp ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Inc) - Forward Price-to-Revenue Multiple|IRADIMED CORPORATION - Forward Price to Sales|EMBC (Embecta Health) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Tandem Diabetes Care Inc TNDM|Price-to-Projected Revenue Ratio AxoGen Inc (AXGN)|SI-BONE, Inc. (SIBN) - Projected Price to Revenue|Orthofix Corp - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio bioventus.com (BVS)|OrthoPediatrics Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Treace Medical Concepts Inc TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed Medical)|Price-to-Projected Revenue Ratio rxsight.com|Forward Price-to-Revenue Multiple ClearPoint Neuro, Inc. (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical - Price to Expected Revenue Ratio|VANI (Vivani Medical Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue XTNT|NMTC (n1mtc.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Modular Medical MODD|Price-to-Projected Revenue Ratio myomo.com (MYO)|Price-to-Projected Revenue Ratio COCH (envoymedical.com)|Price-to-Projected Revenue Ratio Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple
